Aktis Oncology has entered a potential $1 billion collaboration agreement with Eli Lilly to generate anticancer radiopharmaceuticals using its miniprotein technology platform.
The collaboration will draw on Aktis' proprietary radiopharmaceutical platform with Lilly's expertise in oncology drug development and commercialization to develop first-in-class and differentiated therapeutics for a range of solid tumors, the company said.
Under the terms of the deal, Aktis will receive a $60 million upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. Aktis also will be eligible to receive up to an additional $1.1 billion in potential preclinical, clinical, regulatory, and commercial milestones, as well as tiered royalties, it noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
